ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bousquet, J
Right arrow Articles by Lutsky, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bousquet, J
Right arrow Articles by Lutsky, B.
Eur Respir J 2000; 16: 808-816
Copyright © ERS Journals Ltd 2000

Clinical Trial

Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler

J Bousquet, A D'Urzo, J Hebert, CH Barraza, LP Boulet, R Suarez-Chacon, U Harnest, B Lundback, G Martinez Morales, MM Nieminen, KB Nolop, S Visser, and BN Lutsky

Mometasone furoate (MF) administered by dry powder inhaler (DPI) was composed with budesonide (BUD) Turbuhaler in the treatment of moderate persistent asthma. The patients were randomized to one of four treatment groups: MF DPI (100, 200, 400 microg b.i.d) or BUD Turbuhaler. 400 microg b.i.d in a 12-week, active-controlled, evaluator-blind, multicentre international trial. The primary efficacy variable was the mean change from baseline to endpoint (last treatment visit) in forced expiratory volume in one second (FEV1). Changes in FEV1 showed a statistically significant superiority (p<0.05) of MF DPI 200 and 400 microg b.i.d compared with the BUD Turbuhaler 400 microg b.i.d treatment. Significant superiority (p<0.05) was also seen in scores for several secondary efficacy variables when MF DPI was compared with BUD Turbuhaler treatment. MF DPI 200 microg b.i.d was comparable to MF DPI 400 microg b.i.d in therapeutic benefit. The incidence of oral candidiasis was no more than 3% in any group. All treatments were well tolerated. A total daily dose of 400 microg of mometasone furoate administered by dry powder inhaler provides a well-tolerated treatment for patients with moderate persistent asthma and results in a significantly greater improvement, when compared to a daily dose of 800 microg BUD Turbuhaler in the parameters measured in this study.


This article has been cited by other articles:


Home page
 ThoraxHome page
S. O Shaheen, R. B Newson, M. P Rayman, A. P-L Wong, M. K Tumilty, J. M Phillips, J. F Potts, F. J Kelly, P. T White, and P. G J Burney
Randomised, double blind, placebo-controlled trial of selenium supplementation in adult asthma
Thorax, June 1, 2007; 62(6): 483 - 490.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
H. Derendorf, R. Nave, A. Drollmann, F. Cerasoli, and W. Wurst
Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma.
Eur. Respir. J., November 1, 2006; 28(5): 1042 - 1050.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
R. S. Irwin and N. D. Richardson
Side Effects With Inhaled Corticosteroids: The Physician's Perception
Chest, July 1, 2006; 130(1_suppl): 41S - 53S.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
L-G. Carlsson and S. Edsbacker
Comparative efficacy and safety of mometasone furoate dry powder inhaler and budesonide Turbuhaler(R)
Eur. Respir. J., June 1, 2001; 17(6): 1332 - 1333.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the European Respiratory Society.